Viewing Study NCT01423851

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 11:55 PM
Ignite Modification Date: 2026-06-16 @ 9:13 PM
Study NCT ID: NCT01423851
Status: COMPLETED
Last Update Posted: 2022-03-09
First Post: 2011-08-15
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Sponsor: NS Pharma, Inc.
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Primary Myelofibrosis View
None Post-Polycythemia Vera Myelofibrosis View
None Post-Essential Thrombocythemia Myelofibrosis View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Keywords provided by NS Pharma, Inc.: View
None JAK2 kinase inhibitor View
None NS-018 View
None Myeloproliferative Neoplasms View
None Primary Myelofibrosis View
None post-Polycythemia Vera Myelofibrosis View
None post-Essential Thrombocythemia Myelofibrosis View
None Additional relevant MeSH terms: View
None Bone Marrow Diseases View
None Hematologic Diseases View
None Polycythemia Vera View
None Thrombocythemia, Essential View
None PMF View
None post-PV MF View
None post-ET MF View